Key Points
- Director Rodney Hochman bought 1,618 shares of GE HealthCare Technologies on May 12 at an average price of $62.03, totaling about $100,365. The filing indicates he now directly owns 1,618 shares.
- GEHC shares were trading near $61.89, close to their 52-week low of $58.75 and well below the 52-week high of $89.77. The stock also sits below both its 50-day and 200-day moving averages.
- The company’s latest quarterly results showed EPS of $0.99, missing analyst expectations, while revenue of $5.13 billion came in above estimates and rose 7.4% year over year. Analysts currently have a consensus Hold rating with an average price target of $80.67.
GE HealthCare Technologies Inc. (NASDAQ:GEHC - Get Free Report) Director Rodney Hochman acquired 1,618 shares of GE HealthCare Technologies stock in a transaction on Tuesday, May 12th. The stock was purchased at an average price of $62.03 per share, with a total value of $100,364.54. Following the transaction, the director directly owned 1,618 shares in the company, valued at approximately $100,364.54. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
GE HealthCare Technologies Price Performance
Shares of GEHC stock opened at $61.89 on Thursday. The stock has a 50 day moving average of $70.26 and a two-hundred day moving average of $76.95. The company has a current ratio of 1.22, a quick ratio of 0.95 and a debt-to-equity ratio of 0.95. GE HealthCare Technologies Inc. has a 12 month low of $58.75 and a 12 month high of $89.77. The company has a market capitalization of $28.15 billion, a P/E ratio of 14.81, a P/E/G ratio of 1.40 and a beta of 0.74.
GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $0.99 EPS for the quarter, missing analysts' consensus estimates of $1.07 by ($0.08). GE HealthCare Technologies had a return on equity of 20.46% and a net margin of 9.10%.The firm had revenue of $5.13 billion during the quarter, compared to the consensus estimate of $5.04 billion. During the same quarter in the prior year, the business posted $1.01 EPS. GE HealthCare Technologies's revenue was up 7.4% compared to the same quarter last year. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. As a group, equities analysts expect that GE HealthCare Technologies Inc. will post 4.89 EPS for the current year.
Institutional Investors Weigh In On GE HealthCare Technologies
Hedge funds and other institutional investors have recently bought and sold shares of the business. Laurel Wealth Advisors LLC acquired a new stake in GE HealthCare Technologies during the 4th quarter valued at $26,000. Optima Capital LLC acquired a new stake in GE HealthCare Technologies during the 4th quarter valued at $27,000. Godfrey Financial Associates Inc. acquired a new stake in GE HealthCare Technologies during the 4th quarter valued at $27,000. Montag A & Associates Inc. increased its holdings in GE HealthCare Technologies by 105.4% during the 4th quarter. Montag A & Associates Inc. now owns 341 shares of the company's stock valued at $28,000 after purchasing an additional 175 shares in the last quarter. Finally, Transamerica Financial Advisors LLC increased its holdings in GE HealthCare Technologies by 331.6% during the 4th quarter. Transamerica Financial Advisors LLC now owns 341 shares of the company's stock valued at $28,000 after purchasing an additional 262 shares in the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research firms recently commented on GEHC. Oppenheimer restated an "outperform" rating and set a $85.00 target price on shares of GE HealthCare Technologies in a research report on Thursday, April 30th. Jefferies Financial Group cut their target price on GE HealthCare Technologies from $105.00 to $90.00 in a research report on Thursday, April 30th. HSBC cut their target price on GE HealthCare Technologies from $100.00 to $90.00 in a research report on Thursday, April 30th. Barclays cut their target price on GE HealthCare Technologies from $87.00 to $78.00 and set an "equal weight" rating for the company in a research report on Thursday, April 30th. Finally, Stifel Nicolaus set a $80.00 target price on GE HealthCare Technologies in a research report on Wednesday, April 29th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $80.67.
View Our Latest Research Report on GE HealthCare Technologies
GE HealthCare Technologies Company Profile
(
Get Free Report)
GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.
In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
